In contrast to transgenetic mouse models driven by other oncogenes that usually develop tumors around 3 to 6 months after birth, the lung-specific EML4-ALK transgenetic mice have develop multiple lung cancer nodules in both lungs without latency after birth, and inhibition of ALK leads to dramatic tumor regression in vivo. Here, EML4 is linked to lung carcinoma.